Sosei to acquire Heptares for up to $400M

Sosei Group Corp. (Tokyo:4565) will acquire Heptares Therapeutics Ltd. (Welwyn Garden City, U.K.) for $180 million up front and up to $220 million in milestones.

Sosei will receive Heptares' StaR drug discovery platform targeting GPCRs and a diverse early stage pipeline encompassing neuroscience, metabolic and Orphan disease areas. ...